Tetsunaga Tomoko, Tetsunaga Tomonori, Tanaka Masato, Ozaki Toshifumi
Department of Orthopaedic Surgery, Okayama University Hospital, 2-5-1 Shikata-cho, Kitaku, Okayama, 700-8558, Japan.
J Orthop Sci. 2015 Mar;20(2):281-6. doi: 10.1007/s00776-014-0674-4. Epub 2015 Feb 3.
Tramadol-acetaminophen tablets are currently used to treat pain, including that of degenerative lumbar disease. Although there are many reports on tramadol-acetaminophen tablets, treatment outcomes in low back pain (LBP) patients with depression remain uncertain. This study investigated the outcomes of LBP patients with depression treated with tramadol-acetaminophen tablets.
Of 95 patients with chronic LBP, 70 (26 men, 44 women; mean age 64 years) who were judged as having depression by the Self-Rating Depression Scale (SDS) were included in this study. In this trial, patients received one of two randomly assigned 8-week treatment regimes: tramadol-acetaminophen (Tramadol group, n = 35) and non-steroidal anti-inflammatory drugs (NSAIDs) (NSAID group, n = 35). In addition to completing self-report questionnaires, patients provided demographic and clinical information. All patients were assessed using a Numerical Rating Scale (NRS), Oswestry Disability Index (ODI), Pain Disability Assessment Scale (PDAS), Hospital Anxiety and Depression Scale (HADS), SDS, and Pain Catastrophizing Scale (PCS).
After 8 weeks' treatment, the NRS and SDS scores were lower in the Tramadol group than in the NSAID group (p < 0.05). There were no significant differences in the ODI, PDAS, and PCS scores between the groups (p = 0.47, 0.09, 0.47). Although there was no difference in the anxiety component of the HADS between the groups (p = 0.36), the depression component was lower in the Tramadol group than in the NSAID group (p < 0.05). There was no significant difference between groups in the percentage of patients with treatment-associated adverse events.
This investigation found that tramadol-acetaminophen is effective for reducing LBP and provided a prophylactic antidepressant effect in chronic LBP patients with depression.
曲马多-对乙酰氨基酚片目前用于治疗疼痛,包括退行性腰椎疾病引起的疼痛。尽管关于曲马多-对乙酰氨基酚片的报道很多,但抑郁症伴下腰痛(LBP)患者的治疗效果仍不明确。本研究调查了曲马多-对乙酰氨基酚片治疗抑郁症伴LBP患者的效果。
在95例慢性LBP患者中,70例(26例男性,44例女性;平均年龄64岁)通过自评抑郁量表(SDS)判定为患有抑郁症,纳入本研究。在本试验中,患者接受两种随机分配的8周治疗方案之一:曲马多-对乙酰氨基酚(曲马多组,n = 35)和非甾体抗炎药(NSAIDs)(NSAIDs组,n = 35)。除了完成自我报告问卷外,患者还提供了人口统计学和临床信息。所有患者均使用数字评分量表(NRS)、Oswestry功能障碍指数(ODI)、疼痛功能障碍评估量表(PDAS)、医院焦虑抑郁量表(HADS)、SDS和疼痛灾难化量表(PCS)进行评估。
治疗8周后,曲马多组的NRS和SDS评分低于NSAIDs组(p < 0.05)。两组之间的ODI、PDAS和PCS评分无显著差异(p = 0.47、0.09、0.47)。尽管两组之间HADS的焦虑分量表无差异(p = 0.36),但曲马多组的抑郁分量表低于NSAIDs组(p < 0.05)。治疗相关不良事件患者的百分比在两组之间无显著差异。
本研究发现曲马多-对乙酰氨基酚对减轻LBP有效,并对慢性LBP伴抑郁症患者具有预防性抗抑郁作用。